{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:26:21Z","timestamp":1778797581473,"version":"3.51.4"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.critrevonc.2023.104042","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T19:16:42Z","timestamp":1685819802000},"page":"104042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Challenges in the management of primary central nervous system lymphoma"],"prefix":"10.1016","volume":"188","author":[{"given":"Xuefei","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1703-6774","authenticated-orcid":false,"given":"Yuanbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2023.104042_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T Cells in CNS diffuse large-b-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib3","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib4","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","author":"Abrey","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104042_bib5","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-018-2856-y","article-title":"A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome","volume":"139","author":"Adhikari","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers13205061","article-title":"Emerging landscape of immunotherapy for primary central nervous system lymphoma","volume":"13","author":"Alcantara","year":"2021","journal-title":"Cancers"},{"issue":"6769","key":"10.1016\/j.critrevonc.2023.104042_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12987-017-0064-3","article-title":"Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease","volume":"14","author":"Ambady","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.critrevonc.2023.104042_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers13112665","article-title":"Liquid biopsy and other non-invasive diagnostic measures in PCNSL","volume":"13","author":"Baraniskin","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib11","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","article-title":"Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system","volume":"117","author":"Baraniskin","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104042_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/jns.2000.92.2.0261","article-title":"Primary intracerebral malignant lymphoma: report of 248 cases","volume":"92","author":"Bataille","year":"2000","journal-title":"J. Neurosurg."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib13","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.3324\/haematol.2017.185843","article-title":"Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients","volume":"103","author":"Birsen","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104042_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/bjh.17395","article-title":"Real\u2010life targeted next\u2010generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network","volume":"193","author":"Bommier","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104042_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104042_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clml.2020.10.015","article-title":"Primary central nervous system lymphoma: evolving biologic insights and recent therapeutic advances","volume":"21","author":"Chihara","year":"2021","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11060-019-03257-1","article-title":"Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation","volume":"144","author":"Correa","year":"2019","journal-title":"J. Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104042_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2023.104042_bib21","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"S: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2023.104042_bib22","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/cncr.30695","article-title":"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission","volume":"123","author":"DeFilipp","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.104042_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.3083","article-title":"Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: a systematic review and meta-analysis","volume":"41","author":"Epperla","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2023.104042_bib24","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104042_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000055310","article-title":"Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients","volume":"60","author":"Ferreri","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2023.104042_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.wnl.0000210464.94122.e1","article-title":"MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas","volume":"66","author":"Ferreri","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2010.01.066","article-title":"Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy","volume":"80","author":"Ferreri","year":"2011","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104042_bib28","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib29","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib30","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104042_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104042_bib33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104042_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","article-title":"Ibrutinib brain distribution: a preclinical study","volume":"81","author":"Goldwirt","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"25","key":"10.1016\/j.critrevonc.2023.104042_bib35","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/noy192","article-title":"Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104042_bib38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3109\/0284186X.2014.990110","article-title":"Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study","volume":"54","author":"Harjama","year":"2015","journal-title":"Acta Oncol. (Stockh., Swed. )"},{"issue":"21","key":"10.1016\/j.critrevonc.2023.104042_bib39","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib40","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00432-017-2423-5","article-title":"Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial","volume":"143","author":"Herrlinger","year":"2017","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib42","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib43","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104042_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","article-title":"Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study","volume":"133","author":"Houillier","year":"2017","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104042_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib46","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00277-019-03667-1","article-title":"Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma","volume":"98","author":"Hyung","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib47","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.104042_bib48","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2022-165256","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed\/refractory primary and secondary central nervous system lymphoma (CNSL)","volume":"140","author":"Jacobson","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib49","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib50","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2017.101","article-title":"High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom","volume":"52","author":"Kassam","year":"2017","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104042_bib51","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.bbmt.2020.08.012","article-title":"Outcomes of autologous stem cell transplant consolidation in primary central nervous system lymphoma: a mayo clinic experience","volume":"26","author":"Khurana","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.critrevonc.2023.104042_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2141.2004.05284.x","article-title":"Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma","volume":"128","author":"Korfel","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104042_bib53","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/WNL.0000000000001395","article-title":"Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma","volume":"84","author":"Korfel","year":"2015","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104042_bib54","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II Trial of Temsirolimus for Relapsed\/Refractory Primary CNS Lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/2159-8290.CD-17-0714","article-title":"Spotlight on Ibrutinib in PCNSL: adding Another Feather to Its Cap","volume":"7","author":"Lakshmanan","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2023.104042_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diagnostics10121076","article-title":"Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features","volume":"10","author":"Lauw","year":"2020","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104042_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5045\/br.2021.2021073","article-title":"R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience","volume":"56","author":"Lee","year":"2021","journal-title":"Blood Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104042_bib58","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00234-020-02377-0","article-title":"Atypical radiological findings of primary central nervous system lymphoma","volume":"62","author":"Lin","year":"2020","journal-title":"Neuroradiology"},{"key":"10.1016\/j.critrevonc.2023.104042_bib59","article-title":"Efficacy and safety of autologous stem-cell transplantation as part of first-line treatment for newly diagnosed primary central nervous system lymphoma: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3892\/ijo.2021.5180","article-title":"Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review)","volume":"58","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"32","key":"10.1016\/j.critrevonc.2023.104042_bib61","doi-asserted-by":"crossref","first-page":"22850","DOI":"10.18632\/oncotarget.25230","article-title":"Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review","volume":"9","author":"Lopez-Santillan","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104042_bib62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658234","article-title":"Clinical application of liquid biopsy in non-hodgkin lymphoma","volume":"11","author":"Lv","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.707285","article-title":"Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: a PRISMA-compliant single-arm meta-analysis","volume":"11","author":"Lv","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib65","article-title":"Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis","author":"Lv","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3174\/ajnr.A4450","article-title":"The combined performance of ADC, CSF CXC chemokine ligand 13, and CSF interleukin 10 in the diagnosis of central nervous system lymphoma","volume":"37","author":"Mabray","year":"2016","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104042_bib67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers13143479","article-title":"Primary central nervous system lymphoma in elderly patients: management and perspectives","volume":"13","author":"Morales-Martinez","year":"2021","journal-title":"Cancers"},{"issue":"31","key":"10.1016\/j.critrevonc.2023.104042_bib69","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s40064-016-1954-6","article-title":"Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study","volume":"5","author":"Nakasu","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.critrevonc.2023.104042_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104042_bib72","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib--findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib73","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104042_bib74","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","article-title":"Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)","volume":"38","author":"Omuro","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104042_bib76","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s10147-021-01982-0","article-title":"Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study","volume":"26","author":"Piriyakhuntorn","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib77","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: european Organization for Research and Treatment of Cancer Lymphoma Group Phase II trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104042_bib78","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuros\/nyy096","article-title":"Craniotomy and survival for primary central nervous system lymphoma","volume":"84","author":"Rae","year":"2019","journal-title":"Neurosurgery"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104042_bib79","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/djt165","article-title":"Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma","volume":"105","author":"Rancea","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib80","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","article-title":"Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial","volume":"79","author":"Roth","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.104042_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104042_bib82","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","article-title":"CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2023.104042_bib83","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-014-1622-z","article-title":"Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system","volume":"121","author":"Sasagawa","year":"2015","journal-title":"J. Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib85","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/neuonc\/nor203","article-title":"Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)","volume":"14","author":"Sasayama","year":"2012","journal-title":"Neuro-Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104042_bib86","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hon.2666","article-title":"Rituximab in primary central nervous system lymphoma-a systematic review and meta-analysis","volume":"37","author":"Schmitt","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104042_bib87","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2015-01-622498","article-title":"Treatment of primary CNS lymphoma","volume":"125","author":"Schmitz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104042_bib88","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transpl."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104042_bib89","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","article-title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study","volume":"4","author":"Schorb","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib90","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0609.2010.01475.x","article-title":"Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas","volume":"85","author":"Schroers","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A systematic approach to the diagnosis of suspected central nervous system lymphoma","volume":"70","author":"Scott","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib92","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.2147\/CMAR.S255482","article-title":"High Level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma","volume":"12","author":"Shao","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104042_bib93","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib94","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11912-021-01116-9","article-title":"Treatment of primary CNS lymphoma: maximizing clinical benefit, minimizing neurotoxicity","volume":"23","author":"Song","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2023.104042_bib95","doi-asserted-by":"crossref","first-page":"38671","DOI":"10.1038\/srep38671","article-title":"Cerebrospinal Fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104042_bib96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s12185-017-2316-z","article-title":"Effect of rituximab on primary central nervous system lymphoma: a meta-analysis","volume":"106","author":"Song","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib97","article-title":"Non-myeloablative chemotherapy as consolidation strategy after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: a retrospective single center study in China","volume":"12","author":"Sun","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104042_bib98","doi-asserted-by":"crossref","unstructured":"Suzuki Y., Imoto N., Ishihara S., Fujiwara S., Ito R., Sakai T., Yamamoto S., Sugiura I., Kurahashi S.: A. Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma. Internal medicine (Tokyo, Japan) 2021.","DOI":"10.2169\/internalmedicine.7805-21"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104042_bib99","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2023.104042_bib100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104042_bib101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/cancers13081920","article-title":"The role of rituximab in the treatment of primary central nervous system lymphoma","volume":"13","author":"Van Dijck","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2023.104042_bib102","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cancers13123073","article-title":"Targeted therapies and immune checkpoint inhibitors in primary CNS lymphoma","volume":"13","author":"Wirsching","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2023.104042_bib103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-018-2970-x","article-title":"Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial","volume":"140","author":"Wu","year":"2018","journal-title":"J. Neurooncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104042_bib104","doi-asserted-by":"crossref","first-page":"9143","DOI":"10.1002\/jcp.29790","article-title":"Advances and challenges in the treatment of primary central nervous system lymphoma","volume":"235","author":"Yang","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104042_bib105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/bmt.2010.71","article-title":"Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience","volume":"46","author":"Yoon","year":"2011","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib107","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41598-020-80724-0","article-title":"High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials","volume":"11","author":"Yu","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib108","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-021-00282-z","article-title":"Current and emerging therapies for primary central nervous system lymphoma","volume":"9","author":"Yuan","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2023.104042_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers11111647","article-title":"Tumor and cerebrospinal fluid microRNAs in primary central nervous system lymphomas","volume":"11","author":"Zajdel","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104042_bib110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12885-022-09275-z","article-title":"The PI3K\/AKT\/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:37:10Z","timestamp":1778794630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":110,"alternative-id":["S1040842823001300"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104042","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the management of primary central nervous system lymphoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104042"}}